This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: I32 (Pericarditis in diseases classified elsewhere) | Special Copayment Reduction: V192 (Special copayment reduction for heart disease: 5% copayment for up to 30 days from the registration date) |
| B. Synonyms | Secondary pericarditis, lupus pericarditis, uremic pericarditis, tuberculous pericarditis (separate code), pericarditis in systemic disease |
| C. Adult onset | Pericardial inflammation arising secondarily during the course of various systemic diseases (autoimmune, metabolic, infectious, neoplastic); it appears mainly in adulthood in populations with the underlying disease and is closely linked to the prognosis of the underlying disease. |
| 1. History | History of the recognition of secondary pericarditis in rheumatic diseases, renal failure, and systemic infections; the position of secondary pericarditis in the ICD classification code system |
| 2. Causes | Autoimmune diseases such as SLE, RA, and systemic sclerosis, uremia, malignancy, hypothyroidism, sarcoidosis, and amyloidosis are the main underlying diseases |
| 3. Genetics | HLA genotypes conferring susceptibility to the underlying autoimmune disease (HLA-DR2/3) and SLE-associated C1q/C2/C4 deficiency contribute to the risk of lupus pericarditis |
| 4. General epidemiology | Pericardial involvement occurs in about 25–40% of SLE patients; uremic pericarditis in 5–10% of end-stage renal disease patients on dialysis; morbidity differs by underlying disease |
| 5. Pathophysiology | Differs by disease: autoimmune immune complex deposition (SLE), direct irritation by uremic toxins (uremic), metabolic abnormality (hypothyroidism), direct tumor invasion |
| 6. Symptoms | Chest pain and dyspnea added to the symptoms of the underlying systemic disease; pleuropericardial chest pain in SLE, a relatively asymptomatic course common in uremic cases |
| 7. Signs | Pericardial friction rub, fever, findings related to pericardial effusion; accompanied by signs of the underlying disease (lupus butterfly rash, uremic bleeding tendency, etc.) |
| 8. Screening | Regular cardiac evaluation of patients with the underlying disease; immediate ECG, echocardiography, and inflammatory markers when chest pain or dyspnea develops |
| 9. Diagnosis | Pericardial lesions confirmed by echocardiography and CMR; cause of secondary pericarditis established by tests specific to the underlying disease (autoantibodies, renal function, thyroid function) |
| 10. Treatment | Treatment of the underlying disease is the top priority; steroids and immunosuppressants for SLE, intensified dialysis for uremic cases, thyroid hormone replacement for hypothyroidism |
| 11. Prognosis | Prognosis determined by response to treatment of the underlying disease; SLE and uremic pericarditis have a good prognosis with early treatment; pericardial involvement by malignancy is poor |
| 12. Prevention | Active management and early treatment of the underlying disease are key to preventing secondary pericarditis; early detection of pericardial complications through regular cardiac evaluation |
| 13. References | Doria A, et al. Cardiac involvement in systemic lupus erythematosus … and 9 other papers |
Pericarditis in diseases classified elsewhere (ICD I32) is understood, as a complication of various systemic diseases, together with the history of each underlying disease. Historically, uremic pericarditis has long been recognized as a fatal complication of renal failure. In the 19th century, pericardial friction rub and pericardial effusion in patients with chronic renal failure were described as findings appearing shortly before death and were understood as cardiac complications of Bright's disease. With the development of hemodialysis (first successful case in 1945, Willem Kolff) and peritoneal dialysis, the life span of patients with renal failure was extended, but uremic pericarditis remains a serious complication that also occurs in dialysis patients.
Research into lupus cardiac involvement began in earnest when Libman and Sacks described nonrheumatic verrucous endocarditis (Libman-Sacks endocarditis) in SLE in 1924. Pericarditis was recognized as the most common form of cardiac involvement in SLE, and the introduction of corticosteroids in the mid-20th century greatly improved treatment outcomes for SLE-associated pericarditis. Systematic research on cardiac involvement in rheumatoid arthritis also accumulated rapidly in the late 20th century with advances in magnetic resonance imaging and echocardiography.
Hypothyroid pericardial effusion occurs in severe hypothyroidism (myxedema) and declined markedly after the spread of thyroid hormone treatment in the 1950s. Pericardial involvement by malignancy is being observed more often with improved cancer survival, and pericardial complications caused by immuno-oncology agents (immune checkpoint inhibitors) have recently emerged as an important clinical problem. In the ICD-10 classification system, I32 has a dual-coding structure in which the underlying disease is additionally assigned a separate code, so the method of coding pericarditis and the underlying disease simultaneously was adopted.
The underlying diseases of secondary pericarditis under ICD I32 are very diverse. Autoimmune diseases form the most important category, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), mixed connective tissue disease (MCTD), Sjögren syndrome, polymyositis/dermatomyositis, and antiphospholipid syndrome. The incidence of pericarditis is highest in SLE, with pericardial involvement occurring during the course in about 25–40% of all SLE patients.
Uremic pericarditis occurs due to pericardial irritation by uremic substances in predialysis patients whose glomerular filtration rate has fallen severely below 10mL/min/1.73m². Dialysis-associated pericarditis occurs in patients already on dialysis and may appear with inadequate dialysis or within a few weeks after starting dialysis. Malignancy-associated pericardial effusion is common in lung cancer, breast cancer, esophageal cancer, lymphoma, and leukemia, and arises through direct invasion, lymphatic metastasis, and hematogenous metastasis. Cardiac radiotherapy is also an important cause of secondary pericardial disease but is generally coded as I31.
In hypothyroidism, pericardial effusion is particularly common in undiagnosed or untreated severe hypothyroidism and is caused by reduced serum albumin and increased pericardial permeability. Sarcoidosis causes systemic granulomatous inflammation including the pericardium, and pericardial involvement occurs in about 10–20% of patients with cardiac sarcoidosis. In amyloidosis, abnormal proteins are deposited in the pericardium, causing pericardial effusion or a thickened pericardium. In the ICD classification, tuberculous pericarditis (A18.84) is classified under a separate code and excluded from I32.
The genetic background of pericarditis in diseases classified elsewhere is determined by the genetic characteristics of the underlying disease. In SLE-associated pericarditis, the most important genetic background is the SLE susceptibility genes. HLA-DR2 (DRB1*1501) and HLA-DR3 (DRB1*0301) of the HLA complex are associated with increased SLE susceptibility, and carriers of these alleles tend to have a higher frequency of multiorgan involvement, including pericardial involvement. Inherited deficiencies of complement C1q, C1r/C1s, C4, and C2 reduce immune complex clearance and increase immune complex deposition in the pericardium, thereby promoting the development of SLE pericarditis.
Other major genes associated with susceptibility to lupus include TREX1 (DNase III; deficient DNA degradation promotes autoimmunity), IRF5 (IFN regulatory transcription factor), STAT4, PTPN22, BLK, and TNFSF13B (BAFF). In rheumatoid arthritis, the PTPN22 W620 variant, PADI4 polymorphisms, and the HLA-DRB1 shared epitope may be associated with a tendency toward extra-articular involvement (including pericarditis). In uremic pericarditis, genetic variants involved in the rate of renal failure progression (e.g., APOL1 G1/G2 variants: increased risk of renal failure in people of African ancestry) have an indirect influence. In pericardial involvement by malignancy, the specific genetic alterations of each cancer type (e.g., EGFR mutations and ALK rearrangements in lung adenocarcinoma) influence the metastatic tendency of the tumor.
The incidence of secondary pericarditis differs greatly according to the underlying disease. Pericardial involvement in SLE is the most common cardiac complication, with a cumulative incidence during the course of about 25–40%, and prospective studies using echocardiography have reported even higher rates (50–60%). Most take the form of mild pericardial effusion, and clinically evident pericarditis occurs in about 20–25% of all SLE patients. In SLE, pericardial involvement tends to occur simultaneously with other organ involvement during flares of disease activity.
Uremic pericarditis was an inevitable complication of end-stage renal failure shortly before death in the era before dialysis treatment. Currently, the incidence of uremic pericarditis in hemodialysis patients is reported at about 5–10%. Dialysis-associated pericarditis can occur even in patients receiving adequate dialysis, and inadequate dialysis, fluid overload, and immunocompromised states are risk factors. Pericardial involvement by malignancy is the most common cause of pericardial effusion in cancer patients, and pericardial involvement is confirmed in about 10–15% at autopsy of patients who died of cancer. The frequency of pericardial involvement is highest in lung cancer (about 35%), followed by breast cancer, esophageal cancer, and lymphoma.
In hypothyroidism, the incidence of pericardial effusion varies with the TSH level, and in severe hypothyroidism (TSH >10mIU/L), mild effusion is found in about 30–50%. Because complete recovery is possible with thyroid treatment, the clinical impact is limited. In patients with sarcoidosis, pericardial involvement occurs in about 10–20% of cardiac sarcoidosis, but it rarely presents as clinically evident pericarditis or tamponade.
The pathogenesis of secondary pericarditis varies according to the underlying disease. The key mechanism of SLE pericarditis is immune complex-mediated pericardial inflammation. In SLE, immune complexes formed by the binding of autoantibodies (anti-dsDNA, anti-Sm, antihistone, etc.) and autoantigens deposit in the pericardium and activate the complement pathway (especially the classical pathway), inducing a local inflammatory response. This leads to pericardial infiltration by neutrophils, monocytes, and mast cells, increased vascular permeability, and exudate formation. Cytokines such as interleukin-1, TNF-α, and IFN-α/γ amplify the inflammation.
In uremic pericarditis, uremic substances accumulated in the blood (uric acid, middle-molecule uremic toxins, β2-microglobulin, phenols, indoles, etc.) exert direct irritation (contact irritation) on pericardial mesothelial cells, causing noninfectious fibrinous pericarditis. Fibrinous exudate in the pericardial cavity is characteristic and may have a hemorrhagic component. Normal pericardial mesothelial cell function and fluid clearance mechanisms are disrupted, and the exudate accumulates. Removal of uremic substances by dialysis rapidly improves the inflammation.
Pericardial involvement by malignancy arises from direct invasion by tumor cells, lymphatic or hematogenous metastasis, and the effects of radiotherapy. Tumor cells destroy the pericardial mesothelial layer and cause hemorrhagic effusion. Overexpression of vascular endothelial growth factor (VEGF) increases vascular permeability and promotes effusion formation. In hypothyroidism, pericardial effusion arises through a mechanism in which protein-rich effusion accumulates due to increased pericardial vascular permeability and impaired lymphatic drainage. Reduced myocardial contractility also accompanies it and affects cardiac function.
The symptoms of secondary pericarditis show a complex pattern in which the systemic symptoms of the underlying disease overlap with symptoms intrinsic to pericarditis. In SLE pericarditis, chest pain, dyspnea, and fever occur simultaneously during SLE flares. The chest pain is sharp and pleuritic (worse on inspiration, relieved by leaning forward), and other SLE symptoms (arthralgia, skin rash, nephritis symptoms) often worsen at the same time. With a large pericardial effusion, dyspnea and orthopnea are prominent.
Uremic pericarditis is characterized by chest pain that is often absent or mild despite a fairly severe pericardial effusion. This may be related to reduced pain perception due to sensory abnormalities, neuropathy, etc. common in uremic patients. Fever and chest pain occur in about 50%, and dyspnea appears as the pericardial effusion increases. In severe cases, symptoms of cardiac tamponade may develop.
Pericardial involvement by malignancy presents variably, from asymptomatic effusion to rapid cardiac tamponade. Pericardial symptoms are often overlooked among other symptoms (dyspnea, cough, generalized fatigue) after a cancer diagnosis. Hypothyroidism-related pericardial effusion is mostly asymptomatic, and other symptoms of hypothyroidism (fatigue, weight gain, cold intolerance, constipation, edema, bradycardia) are the main presenting symptoms.
Physical findings of secondary pericarditis combine signs of the underlying disease and findings due to pericardial involvement. A pericardial friction rub is heard when fibrinous pericardial effusion is present and is particularly audible in uremic pericarditis. With a large pericardial effusion, the rub disappears and heart sounds diminish. In SLE, accompanying findings such as a butterfly-shaped facial rash (malar rash), oral ulcers, alopecia areata, joint swelling, and pleural friction rub suggest the diagnosis.
Systemic signs of uremia include uremic bleeding (petechiae, ecchymoses), a pale, sallow skin color, uremic frost, neurological changes (sleep disturbance, cognitive decline), and pulmonary edema. In malignancy, weight loss and malignancy-specific findings (cutaneous metastatic nodules, lymphadenopathy, hepatomegaly) are observed together. In hypothyroidism, bradycardia, delayed relaxation of tendon reflexes, dry skin, hair loss, macroglossia, and facial edema (myxedema) accompany it. When cardiac tamponade develops, pulsus paradoxus, jugular venous distension, and hypotension appear.
Screening for secondary pericarditis is done through regular cardiac evaluation of patients with the underlying disease. In SLE patients, regular echocardiography is recommended, and immediate echocardiography is performed especially when disease activity flares or new chest symptoms develop. SLE activity markers (elevated anti-dsDNA, decreased complement, elevated ESR/CRP) are evaluated in connection with the possibility of pericardial involvement.
In dialysis patients, pericardial effusion is evaluated immediately by echocardiography when chest pain, dyspnea, or a new heart murmur develops. The possibility of pericardial involvement is also considered in predialysis patients with markedly elevated BUN levels (>60mg/dL). In patients with malignancy, pericardial effusion is followed with regular chest CT or echocardiography in mediastinal cancers and cancers with pleural involvement. With a rapid increase in pericardial effusion or hemodynamic abnormalities, immediate pericardiocentesis is considered. In patients with suspected hypothyroidism, measurement of TSH and free T4 is essential for screening the cause of pericardial effusion.
The definitive diagnosis of secondary pericarditis is made by combining imaging confirmation of the pericardial lesion with tests specific to the underlying disease. Transthoracic echocardiography (TTE) is the first-line test for assessing the extent of pericardial effusion, the presence of cardiac tamponade, and pericardial thickness. The echogenicity of the pericardial effusion helps distinguish hemorrhagic (hyperechoic) from exudative (hypoechoic) effusion. CMR is useful for assessing pericardial inflammation (T1/T2 mapping, LGE), concomitant myocardial involvement, and the character of the pericardial effusion, and in SLE pericarditis, pericardial LGE visualizes the extent of inflammation.
When pericardial fluid analysis is needed for etiologic diagnosis, the specimen obtained by pericardiocentesis is analyzed for cytology, cultures (bacteria, fungi, tuberculosis), cell count and differential, protein and LDH, specific gravity, ADA (to differentiate tuberculosis), and autoantibodies. In diagnosing pericardial involvement by malignancy, pericardial fluid cytology has a fairly high sensitivity of about 60–80%, and pericardial biopsy is used for further diagnosis when cytology is negative. As tests specific to the underlying disease, ANA, anti-dsDNA, and complement C3/C4 are measured in SLE; BUN, creatinine, and eGFR in uremic pericarditis; and TSH and free T4 in hypothyroidism.
In the treatment of secondary pericarditis, treatment of the underlying disease is the top priority. In SLE pericarditis, aspirin (750–1000mg/day) and colchicine (0.5mg twice/day) are used to control acute symptoms, and with moderate or greater pericardial involvement or an overall flare of SLE activity, corticosteroids (prednisolone 0.5–1mg/kg/day) are combined with hydroxychloroquine. In refractory cases, additional immunosuppressants or biologics such as azathioprine, mycophenolate mofetil, and belimumab (anti-BAFF) are used.
The first-line treatment of uremic pericarditis is rapid removal of uremic substances by intensive hemodialysis (once daily, 6–7 times per week). In most cases pericarditis improves with 2–3 weeks of intensive dialysis. NSAIDs carry a risk of further worsening renal function in dialysis patients and are used cautiously, and when cardiac tamponade develops, immediate pericardiocentesis is needed. When inadequate dialysis is the cause, adjustment of the dialysis prescription (achieving the Kt/V target) is important. In hypothyroidism-related pericardial effusion, once thyroid function is normalized with levothyroxine replacement therapy, the effusion is mostly absorbed within several months. Treatment of malignant pericardial effusion combines control of the effusion through pericardiocentesis, placement of a pericardial drainage catheter, and pericardial window surgery with anticancer treatment of the underlying malignancy (chemotherapy, radiotherapy, targeted therapy, immunotherapy).
The prognosis of secondary pericarditis differs greatly according to the type of underlying disease and response to treatment. SLE pericarditis has a relatively good prognosis when it responds to SLE treatment, and most episodes recover completely. However, repeated episodes of pericarditis may occur over the overall course of SLE, and transition to constrictive pericarditis is rare but has been reported. Uremic pericarditis has a good prognosis when intensive dialysis is performed early, and when cardiac tamponade develops, immediate pericardiocentesis can be lifesaving. Recurrence is frequent if inadequate dialysis is not resolved.
The prognosis of pericardial involvement by malignancy is very poor, and median survival after diagnosis is often less than a few months. However, some malignancies (lymphoma, prostate cancer, breast cancer) respond to anticancer treatment and may have a relatively better prognosis. With the development of modern immuno-oncology agents (PD-1/PD-L1 blockers), survival is improving in some cancer types, but when pericardial involvement occurs, the short-term prognosis is still poor. Hypothyroid pericardial effusion has a very good prognosis with thyroid hormone replacement.
The key to preventing secondary pericarditis is a strategy of minimizing the risk of pericardial involvement through active management of the underlying disease. In SLE, comprehensive management—long-term maintenance of hydroxychloroquine (contributes to reducing SLE-related organ involvement), maintenance of appropriate immunosuppressive treatment, sun protection, and infection prevention—reduces the occurrence of pericarditis. In chronic renal failure, protection of renal function (control of diabetes, blood pressure, and lipids; avoidance of nephrotoxic drugs) and timely initiation of renal replacement therapy contribute to preventing uremic pericarditis. In patients already on dialysis, adequate dialysis dose (achieving the Kt/V target), fluid management, and regular echocardiographic follow-up are recommended.
In patients with malignancy, prevention of pericardial involvement is achieved through effective treatment of the cancer itself, so early cancer diagnosis and curative treatment are the best prevention. Early diagnosis of hypothyroidism and appropriate levothyroxine treatment can prevent the development of pericardial effusion. When using immuno-oncology agents, the occurrence of pericardial complications (pericarditis, pericardial effusion) is monitored regularly, and if they occur, immunosuppressants (steroids) are given early to prevent progression to cardiac tamponade.
Doria A, Iaccarino L, Sarzi-Puttini P, et al. Cardiac involvement in systemic lupus erythematosus. Lupus. 2005;14(9):683-686. DOI: 10.1191/0961203305lu2200oa. PMID: 16218466.
Imazio M, Cecchi E, Demichelis B, et al. Myopericarditis versus viral or idiopathic acute pericarditis. Heart. 2008;94(4):498-501. DOI: 10.1136/hrt.2006.104067. PMID: 17540693.
Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases. European Heart Journal. 2015;36(42):2921-2964. DOI: 10.1093/eurheartj/ehv318. PMID: 26320112.
Moder KG, Miller TD, Tazelaar HD. Cardiac involvement in systemic lupus erythematosus. Mayo Clinic Proceedings. 1999;74(3):275-284. DOI: 10.4065/74.3.275. PMID: 10089993.
Maisch B, Ristic AD, Pankuweit S. Evaluation and management of pericardial effusion in patients with neoplastic disease. Progress in Cardiovascular Diseases. 2010;53(2):157-163. DOI: 10.1016/j.pcad.2010.06.003. PMID: 20728700.
Banerjee AK. Uremic pericarditis. Postgraduate Medical Journal. 1985;61(715):377-381. DOI: 10.1136/pgmj.61.715.377. PMID: 3887840.
Tsang TS, Seward JB, Barnes ME, et al. Outcomes of primary and secondary treatment of pericardial effusion in patients with malignancy. Mayo Clinic Proceedings. 2000;75(3):248-253. DOI: 10.4065/75.3.248. PMID: 10725950.
Salem DN, Isner JM, Kasper EK, et al. Antinuclear antibodies in pericardial disease. Chest. 1984;85(2):195-198. DOI: 10.1378/chest.85.2.195. PMID: 6360534.
Johnson M, Ramachandran S. Hypothyroid heart disease. Clinical Medicine Insights: Cardiology. 2015;9:15-19. DOI: 10.4137/CMC.S15062. PMID: 25861224.
Yun JW, Bae EJ, Yang JH, et al. Cardiac complications in Korean patients with systemic lupus erythematosus: a single-center study. Korean Journal of Internal Medicine. 2020;35(2):385-393. DOI: 10.3904/kjim.2018.263. PMID: 30909676.